FDA Clearance Tracker · K231776
Cell-Free DNA BCT
Last checked: Nov 20, 2026Latest source record: Jul 26, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Jul 26, 2024
Substantially Equivalent
Time to decision
406 days
Received Jun 16, 2023. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K231776
- Device name
- Cell-Free DNA BCT
- Applicant
- Streck, Inc.
- Applicant location
- La Vista, NE
- Received
- Jun 16, 2023
- Decided
- Jul 26, 2024
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 862.1676
- Specialty
- Laboratory Medicine & Pathology
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- It is not the first decision under product code QMA. The earliest in FDA's data is DEN200001, decided Aug 7, 2020.
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K231776
- The applicant filed a statement instead of a public summary, or the summary is not at FDA's usual address. Check the FDA record.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Streck, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- MDx-Chex for BCID2510(k)
K212576 · Decided Jan 19, 2022 · 156 days after receipt
Device type: Assayed External Control Material For Microbiology Nucleic Acid Amplification (Nat) Assays (PMN) · Laboratory Medicine & Pathology
1 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.